AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19570628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxysafflor yellow A (HSYA) 70 mg
Number of subjects: 3
Study 19570628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxysafflor yellow A (HSYA) 140 mg
Number of subjects: 3
Study 17517344 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic heart failure (SHF)
Number of subjects: 147
Study 17517344 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic heart failure (DHF)
Number of subjects: 147
Study 17517344 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 147
Study 15498611 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified mail
Number of subjects: 271
Study 15498611 — intervention group
Group type: COMPARATOR
Intervention: Regular mail
Number of subjects: 271
Study 11181472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 5 mg/h
Number of subjects: 61
Study 11181472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 20 mg/h
Number of subjects: 61
Study 11181472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 50 mg/h
Number of subjects: 61
Study 11181472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 100 mg/h
Number of subjects: 61
Study 11181472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 847
Study 9886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes duration
Number of subjects: 847
Study 9886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with insulin or oral hypoglycaemic agents
Number of subjects: 847
Study 9886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater height
Number of subjects: 847
Study 9886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 847
Study 9886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 847
Study 9886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower 2-h plasma insulin
Number of subjects: 847
Study 8299317 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0963 10 mg
Number of subjects: 35
Study 8299317 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0963 25 mg
Number of subjects: 35
Study 8299317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3175860 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (less than 48 hours after admission)
Number of subjects: 165
Study 3175860 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (more than 48 hours after admission)
Number of subjects: 165
Study 4923928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg/day
Number of subjects: 4
Study 4923928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day
Number of subjects: 4
Study 4923928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone 150 mg/day
Number of subjects: 4
Study 4923928 — intervention group
Group type: COMPARATOR
Intervention: Inert substance
Number of subjects: 4
Study 31166116 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot habituation group
Number of subjects: 60
Study 31166116 — intervention group
Group type: EXPERIMENTAL
Intervention: Shod habituation group
Number of subjects: 60
Study 31166116 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 60
Study 29276925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 26193177 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 54
Study 26193177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 54
Study 26193177 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT)
Number of subjects: 54
Study 26193177 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 54
Study 26193177 — intervention group
Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 54
Study 26193177 — intervention group
Group type: COMPARATOR
Intervention: IMT
Number of subjects: 54
Study 23306963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror image overlay guidance
Number of subjects: 113
Study 23306963 — intervention group
Group type: COMPARATOR
Intervention: No guidance (Control)
Number of subjects: 113
Study 21334389 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable shock timing and intensity
Number of subjects: 0
Study 21334389 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable shock timing and intensity
Number of subjects: 0
Study 21334389 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19804626 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)
Number of subjects: 493
Study 19804626 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (3 mg/kg/day)
Number of subjects: 493
Study 19804626 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 493
Study 19804626 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 493
Study 19804626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment success
Number of subjects: 493
Study 17269421 — intervention group
Group type: EXPERIMENTAL
Intervention: Essliver Forte
Number of subjects: 60
Study 15039411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 63
Study 15039411 — intervention group
Group type: COMPARATOR
Intervention: Expanded medical treatment
Number of subjects: 63
Study 10096642 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated EPQ score on the neuroticism subscale, short duration of treatment, slow onset of response to treatment
Number of subjects: 42
Study 10096642 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 42
Study 8677916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (arm IV: i.a. and i.v. MMC + p.o. 5‐FU; arm V: i.v. MMC + p.o. 5‐FU) for rectal cancer
Number of subjects: 1254
Study 8677916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (arm I: i.p. and i.v. MMC + p.o. 5‐FU; arm II: i.v. MMC + p.o. 5‐FU) for colonic cancer
Number of subjects: 1254
Study 8677916 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (arm III for colonic cancer; arm VI for rectal cancer)
Number of subjects: 1254
Study 1848618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir plus recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF)
Number of subjects: 36
Study 1848618 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir alone
Number of subjects: 36
Study 6433099 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate hemodialysis
Number of subjects: 0
Study 6433099 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with uremic blood cells
Number of subjects: 0
Study 6433099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 0
Study 6433099 — intervention group
Group type: EXPERIMENTAL
Intervention: High urea dialysance treatments
Number of subjects: 0
Study 30367258 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBMT (850 nm, 240 J per limb) before each training session
Number of subjects: 24
Study 30367258 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment before each training session
Number of subjects: 24
Study 28880050 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patches
Number of subjects: 30
Study 28880050 — intervention group
Group type: COMPARATOR
Intervention: Sham patches
Number of subjects: 30
Study 25912232 — intervention group
Group type: EXPERIMENTAL
Intervention: MSF (50:40:10 MCT:SO:FO)
Number of subjects: 40
Study 25912232 — intervention group
Group type: COMPARATOR
Intervention: MS (50:50 MCT:SO)
Number of subjects: 40
Study 25912232 — intervention group
Group type: EXPERIMENTAL
Intervention: MSF
Number of subjects: 40
Study 25272070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Anesthesia Device (group 1, n = 30)
Number of subjects: 60
Study 25272070 — intervention group
Group type: COMPARATOR
Intervention: Venipuncture only (group 2, n = 30)
Number of subjects: 60
Study 22455413 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ixekizumab
Number of subjects: 142
Study 22455413 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ixekizumab
Number of subjects: 142
Study 22455413 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ixekizumab
Number of subjects: 142
Study 22455413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 21115906 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 30
Study 18182600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus metformin
Number of subjects: 128
Study 18182600 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone (750 mg/d)
Number of subjects: 128
Study 18182600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus placebo
Number of subjects: 128
Study 18182600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 15684150 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P) therapy
Number of subjects: 30000
Study 12968983 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 18
Study 12968983 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 18
Study 12968983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10952119 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin
Number of subjects: 0
Study 10952119 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/cisplatin
Number of subjects: 0
Study 8932976 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g supplemental calcium daily
Number of subjects: 4589
Study 8932976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4589
Study 2053000 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections of 80 mg triamcinolone acetonide plus 0.5% procaine hydrochloride in saline
Number of subjects: 23
Study 2053000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6407500 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50 mg and 75 mg)
Number of subjects: 17
Study 6407500 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (50 mg and 75 mg)
Number of subjects: 17
Study 6407500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg, 75 mg and 100 mg)
Number of subjects: 17
Study 6407500 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (75 mg)
Number of subjects: 17
Study 31806432 — intervention group
Group type: COMPARATOR
Intervention: fentanyl target‐controlled infusion (fTCI)
Number of subjects: 39
Study 31806432 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB)
Number of subjects: 39
Study 31320597 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT‐107 (autologous dendritic cells pulsed with six synthetic peptide epitopes targeting GBM tumor/stem cell‐associated antigens)
Number of subjects: 124
Study 31320597 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT‐107
Number of subjects: 124
Study 31320597 — intervention group
Group type: COMPARATOR
Intervention: Control (unpulsed DC)
Number of subjects: 124
Study 29759604 — intervention group
Group type: EXPERIMENTAL
Intervention: IRSplus
Number of subjects: 230
Study 29759604 — intervention group
Group type: COMPARATOR
Intervention: VpS
Number of subjects: 230
Study 27030601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior clopidogrel
Number of subjects: 8927
Study 27030601 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel in-hospital
Number of subjects: 8927
Study 27030601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 8927
Study 25356046 — intervention group
Group type: EXPERIMENTAL
Intervention: pH capsule
Number of subjects: 91
Study 25356046 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter and pH capsule
Number of subjects: 91
Study 23257033 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (Ad) group
Number of subjects: 155
Study 23257033 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 23257033 — intervention group
Group type: EXPERIMENTAL
Intervention: PV group
Number of subjects: 155
Study 23257033 — intervention group
Group type: EXPERIMENTAL
Intervention: PV plus Ad group
Number of subjects: 155
Study 23257033 — intervention group
Group type: EXPERIMENTAL
Intervention: PIB group
Number of subjects: 155
Study 23257033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad group
Number of subjects: 155
Study 20402816 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID) and metronidazole (500 mg TID) for 9 days
Number of subjects: 112
Study 20402816 — intervention group
Group type: COMPARATOR
Intervention: 14-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID), metronidazole (500 mg TID), and amoxicillin (1 g BID) for 9 days
Number of subjects: 112
Study 18616522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg x kg(‐1)
Number of subjects: 50
Study 18616522 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 16096454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound (D)
Number of subjects: 201
Study 16096454 — intervention group
Group type: EXPERIMENTAL
Intervention: Static ultrasound (S)
Number of subjects: 201
Study 16096454 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmarks (LM)
Number of subjects: 201
Study 12433733 — intervention group
Group type: EXPERIMENTAL
Intervention: High pretreatment serum concentration of bFGF (S-bFGF >= 17 pg/ml)
Number of subjects: 103
Study 12433733 — intervention group
Group type: COMPARATOR
Intervention: Low pretreatment serum concentration of bFGF (S-bFGF < 17 pg/ml)
Number of subjects: 103
Study 12433733 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with extensive-stage disease and high S-bFGF (>= 17 pg/ml)
Number of subjects: 103
Study 12433733 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with extensive-stage disease
Number of subjects: 103
Study 10341329 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate standard AA (lyophilised)
Number of subjects: 22
Study 10341329 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate standard BB (lyophilised)
Number of subjects: 22
Study 10341329 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate standard CC (liquid preparation)
Number of subjects: 22
Study 10341329 — intervention group
Group type: COMPARATOR
Intervention: Various NAT assays (including Roche Amplicor, Chiron Quantiplex, Organon Teknika NASBA, and in-house assays)
Number of subjects: 22
Study 8444211 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K supplementation at birth (n = 22)
Number of subjects: 80
Study 8444211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) vitamin K supplementation at birth (n = 18)
Number of subjects: 80
Study 8444211 — intervention group
Group type: COMPARATOR
Intervention: Breastfed without supplementation (n = 25)
Number of subjects: 80
Study 8444211 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (n = 15)
Number of subjects: 80
Study 3021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade 4 mg q.i.d.)
Number of subjects: 51
Study 27976591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-intensity laser therapy (HILT) with total energy of 1500 J through three phases/3 sessions/week for three consecutive months
Number of subjects: 30
Study 27976591 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy with the same physical therapy programme
Number of subjects: 30
Study 27179167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of RF and ultrasound cavitation
Number of subjects: 50
Study 27179167 — intervention group
Group type: COMPARATOR
Intervention: Low calorie diet alone (Control)
Number of subjects: 50
Study 25701273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention decision aid including information on overdetection
Number of subjects: 879
Study 25701273 — intervention group
Group type: COMPARATOR
Intervention: Control decision aid including information on breast cancer mortality reduction and false positives
Number of subjects: 879
Study 23265634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT; Coping Cat)
Number of subjects: 438
Study 23265634 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (sertraline [SRT])
Number of subjects: 438
Study 23265634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and medication
Number of subjects: 438
Study 23265634 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 438
Study 23265634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Anxiety Rating Scale (PARS)
Number of subjects: 438
Study 21146164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing and seeing recordings of a Stravinsky solo clarinet piece performed with three distinct expressive styles: restrained, standard, and exaggerated intention.
Number of subjects: 0
Study 21146164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing and seeing the musical performances.
Number of subjects: 0
Study 21146164 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis of emotional responses.
Number of subjects: 0
Study 18648184 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program consisting of four exercises: expression muscles, tongue, salivary glands, and swallowing, conducted over six months.
Number of subjects: 78
Study 18648184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 78
Study 18648184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with 20 or more remaining teeth.
Number of subjects: 78
Study 18648184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with less than 20 remaining teeth.
Number of subjects: 78
Study 16534103 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Coenzyme Q10 (CoQ10) at preferred dose (either 1800 mg or 2700 mg)
Number of subjects: 185
Study 16534103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 12743668 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (10 microg x kg(‐1) x min(‐1))
Number of subjects: 608
Study 12743668 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 608
Study 12743668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 608
Study 10934787 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizyd tabl. 5 mg
Number of subjects: 24
Study 10934787 — intervention group
Group type: COMPARATOR
Intervention: Glibenese tabl. 5 mg
Number of subjects: 24
Study 9887853 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day standardized family-oriented clinical asthma training program with monthly follow-up for six months (Group 1)
Number of subjects: 81
Study 9887853 — intervention group
Group type: EXPERIMENTAL
Intervention: Same clinical training without follow-up interventions (Group 2)
Number of subjects: 81
Study 9887853 — intervention group
Group type: COMPARATOR
Intervention: Regular medical treatment according to international guidelines without a training program (Control Group)
Number of subjects: 81
Study 9887853 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 81
Study 7816355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program averaging 4.5 sessions per week for 12 weeks
Number of subjects: 33
Study 7816355 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 33
Study 7816355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 33
Study 3259856 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (500 mg)
Number of subjects: 12
Study 31623510 — intervention group
Group type: EXPERIMENTAL
Intervention: Production tasks in regions with varying stages of devoicing
Number of subjects: 100
Study 31623510 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception tasks in regions with varying stages of devoicing
Number of subjects: 100
Study 31623510 — intervention group
Group type: EXPERIMENTAL
Intervention: Link between perception and production systems
Number of subjects: 100
Study 30663529 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalling childhood memories (open-ended or structured)
Number of subjects: 0
Study 30663529 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit childhood manipulation
Number of subjects: 0
Study 30663529 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking the perspective of a child
Number of subjects: 0
Study 30663529 — intervention group
Group type: COMPARATOR
Intervention: Taking the perspective of an adult
Number of subjects: 0
Study 28774367 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 60
Study 28774367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate
Number of subjects: 60
Study 28774367 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 60
Study 26083537 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate, 3 mg/kg, administered intravenously 15 minutes before tracheal intubation
Number of subjects: 132
Study 26083537 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 15 minutes before tracheal intubation
Number of subjects: 132
Study 26083537 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate
Number of subjects: 132
Study 26083537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 24693629 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping with calcium hydroxide (CH)
Number of subjects: 30
Study 24693629 — intervention group
Group type: COMPARATOR
Intervention: Indirect pulp capping with wax
Number of subjects: 30
Study 24693629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CH and wax
Number of subjects: 30